Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

History is made with first small left ventricular assist device implant for young patient

27.03.2014

“Today, we’re going to make history,” said 18-year-old Eric Ramos on the day UT Southwestern Medical Center doctors operated on his ailing heart.

Eric, who has Duchenne muscular dystrophy, is one of only three patients in the United States with the condition to receive a battery-operated left ventricular assist device (LVAD) to keep his weakening heart pumping blood through his body. He is the first patient in the country to be given a specific, smaller LVAD, which means doctors would not need to manipulate his diaphragm, which could compromise his already limited pulmonary function.


Dr. Pradeep Mammen, Associate Professor of Internal Medicine in the division of cardiology, holds the same LVAD, Eric Ramos has to help keep his heart pumping blood through his body.

Duchenne muscular dystrophy, a recessive X-linked form of the disease, affects around 1 in 3,600 boys. Diagnosed at age 6, Eric has used a wheelchair for the past seven years because his muscles, including his heart and lungs, are rapidly degenerating. Nevertheless, Eric has the heart of a champion. He views his latest challenge as an “unreal accomplishment” and says he is honored to be part of history, paving the way for other Duchenne patients with advanced heart failure.

Lead surgeon Dr. Dan Meyer, Professor of Cardio Thoracic Surgery and Director of Mechanical Assist Devices, says it took a team to pull Eric through this historic feat. “We had cardiologists, cardiothoracic surgeons, LVAD coordinators, neurologists, pulmonologists, social workers, nutritionists, and a host of nurses and others excited to be a part of this unique opportunity,” Dr. Meyer said. “Delivering advanced medical care to patients like Eric is something you can only do at an institution like UT Southwestern, where we have the experience and the specialized care to perform higher-risk surgeries that other hospitals would not even entertain.”

The decision to operate, however, was not easy. The team members recognized the severity of the situation, but they were put at ease the moment they met Eric. A senior in high school, Eric spends his free time playing video games, tinkering with computers, and hanging out with his friends, just like most teenage boys. But Eric exudes maturity well beyond his years.

“We could see that Eric is a vibrant young man, despite the fact that he is bound to a wheelchair,” Dr. Meyer said. “The tough part was making sure we would increase his quality of life and that undergoing surgery was worth the risks.”

Because of his faith, Eric says he was cool, calm, and collected the day of his surgery. “Hope canceled out my anxiety and fear,” Eric said. “I knew that I was making history, and that one day people were going to read about my case, and to me, it felt good to be a trailblazer.”

Another person in Eric’s corner is Dr. Pradeep Mammen, Associate Professor of Internal Medicine in the division of cardiology and Medical Director of the Neuromuscular Cardiomyopathy Clinic at UT Southwestern.

Dr. Mammen is one of Eric’s biggest advocates. A heart failure/transplant cardiologist with special expertise in the cardiovascular complications that can occur in patients with neuromuscular disorders, Dr. Mammen spent countless hours conducting background research on all the key components needed to ensure Eric would thrive pre- and post-LVAD implantation.

“For me, working with Eric and advocating on his behalf has been one of the highlights of my career,” Dr. Mammen said. “This is a paradigm shift in how we approach the treatment of Duchenne muscular dystrophy patients, as well as patients with other forms of muscular dystrophy. We clearly have moved the field forward in terms of how we treat patients with muscular dystrophy and subsequent heart failure.”

To Dr. Mammen, Eric is proof of the principle that LVADs can help prolong the lives of muscular dystrophy patients. “This procedure has to be done for the right patient, by the right team,” Dr. Mammen said. “Our team flawlessly executed this endeavor for Eric.”

Eric is happy to have a team of health care professionals working hard to make his life better and, of course, for the support of his family and friends at home in Rowlett, Texas.

Today, when Eric looks in the mirror, he says it is “thrilling to see the torque of the pump pushing blood through my body. My whole body pulsates.” He likens this to the body’s response when a sports car accelerates. Eric looks forward to a bright future, including graduating from high school this spring, and he hopes someday to receive a healthy heart via transplantation.

UT Southwestern has played an integral role throughout the relatively short history of LVAD therapy and in the devices’ rapidly evolving technology. UT Southwestern participated in the landmark clinical trial (REMATCH) that led to FDA approval of the first LVAD for destination therapy and was the only North Texas center to participate in the HeartWare Bridge-to-Transplant trial, which was completed in 2012 and led to FDA approval of the device.

To obtain more information on clinical trials and treatments for advanced heart failure at UT Southwestern, contact the University Hospital Heart and Lung Clinic at 214-645-5505.

About UT Southwestern Medical Center

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty includes many distinguished members, including five who have been awarded Nobel Prizes since 1985. Numbering more than 2,700, the faculty is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 91,000 hospitalized patients and oversee more than 2 million outpatient visits a year.

###

Media Contact: Lisa Warshaw
(214) 648-9349
lisa.warshaw@utsouthwestern.edu

Lisa Warshaw | EurekAlert!

Further reports about: FDA LVAD blood dystrophy failure muscular surgery therapy treatments ventricular

More articles from Medical Engineering:

nachricht New investigation of endovenous laser ablation of varicose veins
11.05.2016 | Kazan Federal University

nachricht A laser for your eyes
18.04.2016 | Lomonosov Moscow State University

All articles from Medical Engineering >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Worldwide Success of Tyrolean Wastewater Treatment Technology

A biological and energy-efficient process, developed and patented by the University of Innsbruck, converts nitrogen compounds in wastewater treatment facilities into harmless atmospheric nitrogen gas. This innovative technology is now being refined and marketed jointly with the United States’ DC Water and Sewer Authority (DC Water). The largest DEMON®-system in a wastewater treatment plant is currently being built in Washington, DC.

The DEMON®-system was developed and patented by the University of Innsbruck 11 years ago. Today this successful technology has been implemented in about 70...

Im Focus: Computational high-throughput screening finds hard magnets containing less rare earth elements

Permanent magnets are very important for technologies of the future like electromobility and renewable energy, and rare earth elements (REE) are necessary for their manufacture. The Fraunhofer Institute for Mechanics of Materials IWM in Freiburg, Germany, has now succeeded in identifying promising approaches and materials for new permanent magnets through use of an in-house simulation process based on high-throughput screening (HTS). The team was able to improve magnetic properties this way and at the same time replaced REE with elements that are less expensive and readily available. The results were published in the online technical journal “Scientific Reports”.

The starting point for IWM researchers Wolfgang Körner, Georg Krugel, and Christian Elsässer was a neodymium-iron-nitrogen compound based on a type of...

Im Focus: Atomic precision: technologies for the next-but-one generation of microchips

In the Beyond EUV project, the Fraunhofer Institutes for Laser Technology ILT in Aachen and for Applied Optics and Precision Engineering IOF in Jena are developing key technologies for the manufacture of a new generation of microchips using EUV radiation at a wavelength of 6.7 nm. The resulting structures are barely thicker than single atoms, and they make it possible to produce extremely integrated circuits for such items as wearables or mind-controlled prosthetic limbs.

In 1965 Gordon Moore formulated the law that came to be named after him, which states that the complexity of integrated circuits doubles every one to two...

Im Focus: Researchers demonstrate size quantization of Dirac fermions in graphene

Characterization of high-quality material reveals important details relevant to next generation nanoelectronic devices

Quantum mechanics is the field of physics governing the behavior of things on atomic scales, where things work very differently from our everyday world.

Im Focus: Graphene: A quantum of current

When current comes in discrete packages: Viennese scientists unravel the quantum properties of the carbon material graphene

In 2010 the Nobel Prize in physics was awarded for the discovery of the exceptional material graphene, which consists of a single layer of carbon atoms...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Networking 4.0: International Laser Technology Congress AKL’16 Shows New Ways of Cooperations

24.05.2016 | Event News

Challenges of rural labor markets

20.05.2016 | Event News

International expert meeting “Health Business Connect” in France

19.05.2016 | Event News

 
Latest News

11 million Euros for research into magnetic field sensors for medical diagnostics

27.05.2016 | Awards Funding

Fungi – a promising source of chemical diversity

27.05.2016 | Life Sciences

New Model of T Cell Activation

27.05.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>